EYPTEyePoint, Inc.
$3.40-74% 1Y
$3.40
$3.1552 weeks$18.85
EYPT in its own filings
EYPT's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
614
Events found in the filings · across 1,342 filings · the record starts in 2005
- Hard flags
- 3
Hard flags
- Most recent filing
- Sep 10, 2026
Most recent filing · Form 8-K
- Record starts
- Jan 25, 2005
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)historical
- 2008-06-18
- Late periodic report3 occurrences
- 2021-05-03
- Delisting notice / listing-rule failure2 occurrences
- 2020-06-17
- SEC comment-letter activity37 occurrences
- 2024-08-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 10, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio.Other event · Form 8-K
- Aug 17, 2026On August 17, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing topline data for LUGANO, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD)Other event · Form 8-K
- Jul 30, 2026On July 30, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of diabetic macular edema ("DME")Other event · Form 8-K
- Jul 17, 2026On July 17, 2026 (the “Effective Date”), EyePoint, Inc. (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) with the United States of America, acting through the U.S. Department of Justice (“DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human …Material agreement entered · Form 8-K
- Jun 22, 2026EyePoint, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast (the “Annual Meeting”)Director or officer change · Form 8-K
- May 14, 2026On May 14, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing a positive recommendation from the independent Data Safety Monitoring Committee following completion of its third scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU ™ for the treatment of wet age-related …Other event · Form 8-K
- Apr 13, 2026On April 13, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio.Other event · Form 8-K
- Mar 2, 2026On March 2, 2026, EyePoint, Inc. issued a press release announcing the first patients dosed in both COMO and CAPRI, the Company's Phase 3 clinical trials of DURAVYU TM, formerly EYP-1901, for the treatment of diabetic macular edema ("DME")Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks